Nanobiotix S.A. (NASDAQ:NBTX – Get Free Report)’s stock price rose 3.6% on Tuesday . The company traded as high as $4.36 and last traded at $4.36. Approximately 10,235 shares changed hands during trading, a decline of 42% from the average daily volume of 17,666 shares. The stock had previously closed at $4.21.
Wall Street Analyst Weigh In
Separately, Guggenheim began coverage on shares of Nanobiotix in a research report on Wednesday, August 28th. They set a “buy” rating and a $12.00 price target on the stock.
Check Out Our Latest Research Report on NBTX
Nanobiotix Stock Performance
Nanobiotix Company Profile
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
See Also
- Five stocks we like better than Nanobiotix
- Insider Trading – What You Need to Know
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- The Basics of Support and Resistance
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
